The company
obvioTec AG is a Swiss technology company. Our unique and disruptive technology significantly improves pharma quality control, accelerates control and release processes and reduces cost. As a result, the number of recalls can be reduced and drug- and patient safety is improved. We offer managed "technology as a service".
Our history
idea was born to use terahertz technology for real world applications e.g. authenticity testing of pharmaceutical medicines
incorporation of TERA Group, four founders, HQ Zurich-Zollikon, first market activities & technology experiments
seed money round, proof of concept with technology partners, raising market interest
team extention, move into new lab facility in Hombrechtikon/ZH, test-systems built, acceleration of technical and marketing activities
first contracts signed with global pharma and diagnostics companies
financing company growth and extending market position.
TERA Group AG is now obvioTec AG
FAT passed with an MVP for consumables testing (global diagnostics company)
obvioTec’s Foreign Particle Detection solution has been presented at the PDA* Conference in Baltimore (USA) by a global leading pharma company. ObvioTec’s breakthrough technology has the potential to become a global FDA quality standard for Difficult-to-inspect Parenterals.
Prototype for quality checks in real time using GHz waves (pharmaceutical/cosmetics packages, electronic parts)
*= Parenteral Drug Association, www.pda.org
**=Difficult-to-inspect Parenteral drugs (lyophilized, powder, opaque pharmaceuticals)